Pacira: Q2 earnings snapshot. August 4, 2026, 4:39 PM BRISBANE, Calif. (AP) - BRISBANE, Calif. (AP) - Pacira Pharmaceuticals Inc. (PCRX) on Tuesday reported earnings of $4.7 million in its second quarter. On a per-share basis, the Brisbane, California-based company said it had profit of 12 cents. Earnings, adjusted for one-time gains and costs, came to 73 cents per share. The specialty drugmaker posted revenue of $192.4 million in the period. Pacira expects full-year revenue in the range of $735 million to $760 million. Keep Watching 1 dead, 7 injured after two-vehicle crash in Germantown This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PCRX at https://www.zacks.com/ap/PCRX

Pacira BioSciences Q2 earnings call highlights. August 4, 2026 Key points. * Second-quarter revenue rose 6% to $192.4 million, driven by EXPAREL, ZILRETTA and iovera° sales; adjusted EBITDA was approximately $48.7 million. * EXPAREL continued gaining share despite weakness in elective soft-tissue procedures, supported by growth in outpatient settings and expanded UnitedHealthcare coverage that brought separate reimbursement to more than 150 million covered lives. * Pacira completed the sale of iovera° to Zimmer Biomet and expects up to $140 million in proceeds, while lowering full-year revenue guidance to $735 million-$760 million; three key clinical readouts are expected by year-end. * MarketBeat previews top five stocks to own in September. Pacira BioSciences NASDAQ: PCRX reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet. Total second-quarter revenue rose 6% from the prior-year period to $192.4 million, according to Chief Financial Officer Shawn Cross. The company reported GAAP net income of $4.7 million, or $0.12 per diluted share, and adjusted EBITDA of approximately $48.7 million. EXPAREL net product sales increased 3% to $147.8 million, while volume grew approximately 4%. Cross said the difference between volume and revenue growth reflected vial mix and discounting associated with the company's third group purchasing organization, which began operating in mid-2025. Pacira expects that gap to narrow as it laps the prior-year impact. EXPAREL gains share despite elective-procedure softness. Chief Executive Officer Frank Lee said EXPAREL continued to gain penetration across market segments even as macroeconomic pressure affected certain elective soft-tissue procedures, particularly in hospital inpatient settings. The company said EXPAREL volumes are approximately 60% orthopedic and 40% soft tissue. Chief Commercial Officer Brendan Teehan said orthopedic procedures remained relatively stable during the quarter, while elective soft-tissue procedures slowed, with the declines more pronounced in inpatient hospitals. He attributed the trend in part to softer consumer healthcare spending and broader economic uncertainty affecting deferrable procedures. Pacira said it is concentrating on ambulatory surgery centers, hospital outpatient settings and procedures it considers more resilient to macroeconomic conditions. Teehan said EXPAREL significantly outpaced the broader market in ambulatory surgery centers, where procedure volumes were modestly higher overall. The company also cited progress on reimbursement. UnitedHealthcare expanded EXPAREL coverage to provide separate reimbursement outside the surgical bundle, adding approximately 40 million covered lives. Pacira said EXPAREL now has separate reimbursement for more than 150 million covered lives, or roughly half of medically insured lives in the United States, and remains on track toward its year-end target of 160 million. During the question-and-answer session, Lee said Pacira's outlook does not assume a broad recovery in elective procedures. Instead, the company expects growth from outpatient settings, commercially reimbursed procedures, payer wins and continued share gains. ZILRETTA, iovera° and Partnership Developments. ZILRETTA sales rose 4% to $32.6 million in the quarter. Teehan said growth reflected commercial investments made last year, including a dedicated ZILRETTA sales force and the company's partnership with Johnson & Johnson. UnitedHealthcare also placed ZILRETTA on its preferred drug list, eliminating prior authorization requirements, according to Pacira. Discover more Market Cap Calculator Financial News Subscription iovera° sales grew 21% to $6.8 million. Pacira completed the divestiture of the product to Zimmer Biomet on July 31. Under the transaction, Pacira is eligible to receive up to $140 million, including $70 million upfront and up to $70 million in revenue-based milestones. Lee said the transaction sharpens Pacira's focus on becoming an innovation-driven biopharmaceutical company and allows it to direct capital toward higher-return opportunities. Pacira will continue collaborating with Zimmer Biomet on the iovera° spasticity program, with potential additional compensation tied to clinical and regulatory success. The company also said LG Chem recently submitted a regulatory filing for EXPAREL in South Korea. Pacira expects revenue from that arrangement to begin in 2027 and plans to provide updates on additional international commercial partnerships during the second half of the year. Pipeline readouts expected by year-end. Pacira said it expects three top-line clinical readouts by year-end: a registrational study of iovera° in spasticity, a Phase III study of ZILRETTA in shoulder osteoarthritis, and Part A of the Phase II ASCEND study for PCRX-201 in knee osteoarthritis. Enrollment has been completed in the iovera° spasticity registrational study, while enrollment has opened for Part B of the PCRX-201 Phase II trial. Part A randomized 49 patients to two PCRX-201 dose groups or a saline control. All participants received an intra-articular corticosteroid before treatment, with safety as the primary objective and efficacy endpoints assessed at weeks 38 and 52. Chief Medical Officer Jonathan Slonin said the Part A data are expected at the end of the year and are designed to provide safety insights and assess efficacy trends. Pacira expects to report additional data sets during 2027. The company also said it has established a U.S.-based commercial manufacturing process for PCRX-201 and has begun a pilot efficacy study in canine osteoarthritis. In addition, Pacira plans to begin Phase II development later this year for PCRX-2002, a hydrogel formulation of ropivacaine intended to provide rapid-onset and long-acting postsurgical analgesia from a single instillation into the surgical field. Guidance updated following iovera° sale. Pacira lowered its full-year total revenue guidance to $735 million to $760 million from a previous range of $745 million to $770 million, reflecting the iovera° divestiture. The company maintained its EXPAREL net product sales outlook of $600 million to $620 million. The company reduced its full-year SG&A guidance to $310 million to $330 million, from $320 million to $340 million, and narrowed stock-based compensation guidance to $54 million to $59 million. Pacira reiterated guidance for non-GAAP gross margin of 77% to 79% and non-GAAP research and development expense of $105 million to $115 million. Pacira ended the quarter with $251 million in cash and investments, before the $70 million upfront payment from the Zimmer Biomet transaction. Cross said the company expects the fourth quarter to be its largest dollar contributor for EXPAREL sales, following historical seasonal patterns. About Pacira BioSciences (NASDAQ:PCRX). Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain. In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Pacira BioSciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list. While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Zimmer Biomet has agreed to acquire Pacira BioSciences' iovera pain relief device for up to $140 million, comprising $70 million upfront and up to $70 million in revenue-based milestones through 2031. Iovera uses extreme cold to disrupt pain signals in targeted nerves, treating conditions including knee pain from osteoarthritis or surgery, as well as hip, shoulder, foot and spine pain. The device generated $24.2 million in sales last year, growing 6%. BTIG analyst Ryan Zimmerman noted the acquisition complements Zimmer's orthopaedics portfolio and benefits from legislation expanding access to non-opioid pain treatments. Zimmer will collaborate on Pacira's ongoing spasticity trial, with Pacira eligible for additional compensation upon successful completion and regulatory approval. The deal is expected to close in the third quarter.